BUSINESS

• Ratio of Generic Name Prescribing Up 30% in 2 Doctor Surveys
  June 22, 2012

• Takeda Files MAAs for 2 Fixed-Dose Alogliptin Combination Drugs in Europe
  June 21, 2012

• Takeda to Terminate Development of Anti-HGF Antibody; Return Rights to Galaxy of the US
  June 21, 2012

• Teijin Pharma to Build New Laboratory to Support Increased Feburic Production and New Drug Development
  June 21, 2012

• IBL, Trans Genic to Create Joint Venture for Diagnostic Agent Development and Clinical Tests
  June 21, 2012

• Daiichi Sankyo to Market Ranbaxy Products in Venezuela
  June 21, 2012

• Kyowa Hakko Kirin Reports Significant Decrease in Off Time with Parkinson’s Disease Drug that is Currently Under Approval Review
  June 20, 2012

• RDKK Aims at Sales of 55.5 Billion Yen in 2014 Driven by Personalized Medicine: President Ogasawara
  June 20, 2012

• Concrete Price Negotiations to Get Underway by August or September: President Choufuku of Mediceo
  June 19, 2012

• Nichi-Iko, Mitani Sangyo to Build New Plant in Toyama for APIs
  June 19, 2012

• “Sales, Shares Will Follow” Tohoku ALC Opening: Mediceo President Choufuku
  June 19, 2012

• DSP Obtains Approval for Antipsychotic Drug Latuda in Canada
  June 19, 2012

• Pfizer Japan Top Choice in All Factors Doctors Consider Important When Prescribing Generics: QLife Survey
  June 19, 2012

• Takeda to Cease Distribution of 13 former Wyeth Products, Except for Prevenar, BeneFIX, Enbrel
  June 19, 2012

• [Data] Sales of Takeda’s Mainstay Products in FY2011
  June 19, 2012

• [Data] Sales of Otsuka HD's Mainstay Products in FY2011
  June 19, 2012

• [Data] Sales of Astellas's Mainstay Products in FY2011
  June 19, 2012

• [Data] Sales of Daiichi Sankyo's Mainstay Products in FY2011
  June 19, 2012

• [Data] Sales of Eisai's Mainstay Products in FY2011
  June 19, 2012

• [Data] Sales of Mitsubishi Tanabe's Mainstay Products in FY2011
  June 19, 2012

ページ

• « 先頭
• ‹ Prev
• …
• 646
• 647
• 648
• 649
• 650
• 651
• 652
• 653
• 654
• …
• Next ›
• 最終 »